NovoCure (Nasdaq:NVCR) - Cotización, noticias y análisis

Resumen de acción NVCR

NovoCure Limited, una empresa oncológica, se dedica al desarrollo, la fabricación y la comercialización de dispositivos de campos de tratamiento de tumores (TTFields) para el tratamiento de cánceres de tumores sólidos en Estados Unidos, Alemania, Japón, la Gran China e internacionalmente.

Acerca de la empresa

NVCR fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 9.79%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de NovoCure Limited

Omnicell

NasdaqGS:OMCL

US$1.3b

LeMaitre Vascular

NasdaqGM:LMAT

US$1.5b

NuVasive

NasdaqGS:NUVA

US$2.1b

Integra LifeSciences Holdings

NasdaqGS:IART

US$2.2b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for NovoCure
Historical stock prices
Current Share Price	US$12.64
52 Week High	US$83.60
52 Week Low	US$10.87
Beta	0.43
1 Month Change	-19.16%
3 Month Change	-9.88%
1 Year Change	-81.12%
3 Year Change	-93.76%
5 Year Change	-74.17%
Change since IPO	-30.88%

Noticias y actualizaciones recientes

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08

Recent updates

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

May 28

NovoCure: A Stalwart With More Upsides

May 09

NovoCure: Overview Of The GBM Business

Feb 28

Health Check: How Prudently Does NovoCure (NASDAQ:NVCR) Use Debt?

Feb 14

NovoCure: Time For A Cure

Jan 01

Rentabilidad de los accionistas

	NVCR	US Medical Equipment	Mercado US
7D	6.8%	1.5%	2.0%
1Y	-81.1%	-2.0%	22.3%

Rentabilidad vs. Industria: NVCR obtuvo unos resultados inferiores a los del sector US Medical Equipment , que el año pasado arrojó un rendimiento del -2%.

Rentabilidad vs. Mercado: NVCR obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is NVCR's price volatile compared to industry and market?
NVCR volatility
NVCR Average Weekly Movement	9.2%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de NVCR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NVCR (9%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	1,453	Asaf Danziger	www.novocure.com

NovoCure Limited, una empresa oncológica, se dedica al desarrollo, fabricación y comercialización de dispositivos de campos de tratamiento de tumores (TTFields) para el tratamiento de cánceres de tumores sólidos en Estados Unidos, Alemania, Japón, China e internacionalmente. Los dispositivos TTFields de la empresa incluyen Optune Gio y Optune Lua. También tiene en marcha ensayos clínicos que investigan TTFields en metástasis cerebrales, cáncer gástrico, glioblastoma, cáncer de hígado, cáncer de pulmón no microcítico, cáncer de páncreas y cáncer de ovario.

Resumen de fundamentos de NovoCure Limited

¿Cómo se comparan los beneficios e ingresos de NovoCure con su capitalización de mercado?
Estadísticas fundamentales de NVCR
Capitalización bursátil	US$1.36b
Beneficios(TTM)	-US$207.04m
Ingresos (TTM)	US$509.34m

2.7x

Ratio precio-ventas (PS)

-6.6x

Ratio precio-beneficio (PE)

¿Está NVCR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NVCR
Ingresos	US$509.34m
Coste de los ingresos	US$127.54m
Beneficio bruto	US$381.80m
Otros gastos	US$588.85m
Beneficios	-US$207.04m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 02, 2024

Beneficios por acción (BPA)	-1.92
Margen bruto	74.96%
Margen de beneficio neto	-40.65%
Ratio deuda/patrimonio	156.9%

¿Cómo se ha desempeñado NVCR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NVCR

Recompensas

Análisis de riesgos

Competidores de NovoCure Limited

NasdaqGS:OMCL

US$1.3b

NasdaqGM:LMAT

US$1.5b

NasdaqGS:NUVA

US$2.1b

NasdaqGS:IART

US$2.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Recent updates

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

President notifies of intention to sell stock

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Price target increased to US$98.86

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure: See Past Market Myopia And Buy The Dip

Chief Development Officer notifies of intention to sell stock

Novocure creates new CNS focused franchise to renew growth in brain cancer business